中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Metabolic Diseases
Viral Diseases
Cancer
Exploratory Indications
Products&Pipeline
Pipeline
Products
Clinical Trials
Partnership
Investors
Financials & Filing
News
Careers
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Show More
2014
Gannex Received China IND Approval of Its FXR Agonist ASC42 for NASH Indication
2021-05-27
Clinical Trial Application of ASC40 Combined with Bevacizumab to Treat Patients with Recurrent Glioblastoma Accepted by China NMPA
2021-05-25
Ascletis Announces Positive Phase IIa HBV Results on Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)
2021-05-05
Gannex Announces the First Cohort Dosed in a U.S. Clinical Study with THR-β Agonist ASC41
2021-04-14
Ascletis Announced Four Clinical and Preclinical Study Abstracts of NASH and HBV Accepted as Poster Presentations by the International Liver Congress™ 2021
2021-04-12
Ascletis Announces Investment Escalation in R&D of Cancer Lipid Metabolism and Oral Checkpoint Inhibitors
2021-03-30
Ascletis’ Strategic Partner Sagimet Biosciences Receives Fast Track Designation from U.S. Food and Drug Administration for FASN Inhibitor TVB-2640 in NASH
2021-03-22
FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH
2021-03-09
Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-β Agonist ASC41 for NASH
2021-02-25
Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-β Agonist ASC41
2021-02-21
«
1
2
3
4
»